A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens
Sponsor: Hackensack Meridian Health
Terminated
Low Accrual
Other terminated trials from Hackensack Meridian Health
A PHASE2 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Hackensack Meridian Health and has accumulated 16 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2023 — Feb 2024 [monthly]
Recruiting PHASE2
▶ Show 11 earlier versions
-
Jan 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hackensack Meridian Health
- Janssen, LP
For direct contact, visit the study record on ClinicalTrials.gov .